pravastatin has been researched along with cyclosporine in 68 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 19 (27.94) | 18.2507 |
| 2000's | 25 (36.76) | 29.6817 |
| 2010's | 24 (35.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Bracha, AL; Huang, S; Ingber, DE; Ramanathan, A; Schreiber, SL | 1 |
| Benet, LZ; Brouwer, KL; Chu, X; Dahlin, A; Evers, R; Fischer, V; Giacomini, KM; Hillgren, KM; Hoffmaster, KA; Huang, SM; Ishikawa, T; Keppler, D; Kim, RB; Lee, CA; Niemi, M; Polli, JW; Sugiyama, Y; Swaan, PW; Tweedie, DJ; Ware, JA; Wright, SH; Yee, SW; Zamek-Gliszczynski, MJ; Zhang, L | 1 |
| Annand, R; Gozalbes, R; Jacewicz, M; Pineda-Lucena, A; Tsaioun, K | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Fent, K; Popovic, M; Smital, T; Zaja, R | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Eydelloth, RS; Germershausen, JI; Grossman, SJ; MacDonald, JS; Schwartz, MS; Smith, PF; Stubbs, RJ | 1 |
| Ohmori, Y; Oka, T; Okamoto, M; Yoshimura, N | 1 |
| Alsina, J; Castelao, AM; Castiñeiras, MJ; Cruzado, JM; Fiol, C; Gilvernet, S; Grinyó, JM; Seron, D; Torras, J | 1 |
| Ohmori, Y; Oka, T; Tsuji, T; Yoshimura, N | 1 |
| Campana, C; Gavazzi, A; Iacona, I; Perani, G; Regazzi, MB; Viganò, M | 1 |
| Campana, C; Gavazzi, A; Iacona, I; Lesi, C; Perani, G; Raddato, V; Regazzi, MB; Viganò, M | 1 |
| Ballantyne, CM | 1 |
| Chia, D; Cohen, AH; Hirata, M; Katznelson, S; Kobashigawa, JA; Ozawa, M; Teraski, PI; Wang, XM; Wilkinson, AH; Zhong, HP | 1 |
| Kada, M; Komai, T; Kurakata, S; Nomoto, K; Shimada, Y | 1 |
| Boddaert, M; Christians, U; Doll, R; Eisenhauer, T; Kliem, V; Krekler, M; Mangold, B; O'Grady, P; Olbricht, CJ; Wanner, C | 1 |
| Christians, U | 1 |
| Busuttil, RW; Cai, W; Dawson, S; Imagawa, DK; Kakkis, JL; Kaldas, F; Ke, B; Maggard, M; Sauri, H; Seu, P; Shau, H; Si, M | 1 |
| Boddaert, M; Christians, U; Doll, R; Eisenhauer, T; Kliem, V; Krekler, M; Mangold, B; O'Grady, P; Olbricht, C; Wanner, C | 1 |
| Arita, S; Atiya, A; Kasraie, A; Mullen, Y; Ohtsuka, S; Shevlin, L; Une, S | 1 |
| Chia, D; Hirata, M; Katznelson, S; Kobashigawa, JA; Ozawa, M; Terasaki, PI; Wang, XM; Zhong, HP | 1 |
| Katznelson, S; Perez, R; Ramirez, A; Weiss, R | 1 |
| Anand, R; Burrows, L; Genyk, Y; Knight, R; Moran, V; Schwartz, B | 1 |
| Basile, V; Capone, D; Gentile, A; Imperatore, P; Pellegrino, T; Stanziale, P | 1 |
| Baner, K; Benet, LZ; Christians, U; Deters, M; Hackbarth, I; Hallensleben, K; Jacobsen, W; Kirchner, G; Mancinelli, L; Sewing, KF | 1 |
| Vormfelde, SV | 1 |
| Ijzermans, JN; Vaessen, LM; van Gelder, T; van Miert, PP; Weimar, W | 1 |
| Fricker, FJ; Harker, K; Kahler, DA; Penson, MG; Schowengerdt, KO; Thompson, JR; Williams, BJ | 1 |
| Gerbes, AL; Parhofer, KG; Schwandt, P; Zachoval, R | 1 |
| Arita, S; Kasraie, A; Mullen, Y; Ohtsuka, S; Smith, CV; Une, S | 1 |
| Almenar Bonet, L; Arnau Vives, MA; Dicenta Gisbert, F; Martínez-Dolz, L; Osa Sáez, A; Palencia Pérez, M; Rueda Soriano, J | 1 |
| Gross, W; Harder, S; Krell, B; März, W; Merz, M; Park, JW; Schüler, S; Seidel, D; Siekmeier, R | 1 |
| Bang, BK; Jung, JY; Kim, J; Kim, SB; Kim, YS; Li, C; Lim, SW; Park, JH; Sun, BK; Yang, CW | 1 |
| Antikainen, M; Hedman, M; Holmberg, C; Neuvonen, M; Neuvonen, PJ | 1 |
| Hess, L; Krähenbühl, S; Krähenbühl-Melcher, A; Rätz Bravo, AE; Schlienger, RG; Tchambaz, L | 1 |
| Cha, JH; Kang, DH; Kang, SW; Kim, J; Kim, YS; Li, C; Lim, SW; Song, JC; Sun, BK; Yang, CW | 1 |
| Asberg, A; Hermann, M; Holdaas, H; Lemahieu, WP; Maes, BD; Vanrenterghem, Y; Verbeke, K | 1 |
| Izar, MC | 1 |
| Heemann, U; Kohnle, M; Kribben, A; Philipp, T; Pietruck, F; Witzke, O | 1 |
| Serón, D | 1 |
| Lopau, K; Spindler, K; Wanner, C | 1 |
| Aihara, Y; Harada, T; Inaba, A; Ito, S; Machida, H; Nakamura, T; Okuyama, K; Yokota, S | 1 |
| Iwagaki, H; Kanke, T; Liu, K; Nishibori, M; Takahashi, HK; Tanaka, N; Yagi, T; Yoshino, T | 1 |
| Imai, S; Kitamura, A; Komuro, S; Yabuki, M | 1 |
| Aliabadi, AZ; Dunkler, D; Grimm, M; Grömmer, M; Mahr, S; Wolner, E; Zimpfer, D; Zuckermann, AO | 1 |
| Hayashi, T; Ijiri, Y; Iwamoto, A; Kato, R; Kozu, C; Nishide, M; Suzuki, K; Tanaka, K; Urashima, K | 1 |
| Bouquié, R; Dailly, E; Deslandes, G; Haloun, A; Jolliet, P; Renaud, C | 1 |
| Lin, ZQ; Yang, J; Yin, XF | 1 |
| Bergman, A; Feng, B; Goosen, TC; Lai, Y; Litchfield, J; Varma, MV | 1 |
| Chung, BH; Doh, KC; Hyoung, BJ; Lim, SW; Piao, SG; Yang, CW | 1 |
| Kim, J; Lim, SW; Piao, SG; Song, JH; Yang, CW; Yoon, HE | 1 |
| Chen, TL; Estey, EH; Gardner, KM; Markle, LJ; Othus, M; Walter, RB | 1 |
| Endo, T; Fujii, Y; Haraguchi, K; Kato, Y; Kimura, O; Koga, N; Ohta, C | 1 |
| Asaumi, R; Kotani, N; Kusuhara, H; Maeda, K; Nakada, T; Sugiyama, Y; Toshimoto, K; Yoshida, K; Yoshikado, T | 1 |
| Kato, Y; Kogi, T; Masuo, Y; Nakamichi, N; Taguchi, T | 1 |
| Brian, W; Coelho, A; Giacomini, KM; Giacomini, MM; Goswami, S; Hsueh, CH; Kinchen, JM; Kroetz, DL; Liang, X; Mertsch, K; Weitz, D; Yee, SW; Zur, AA | 1 |
| Chen, EC; Chen, Y; Choo, EF; Liu, L; Ma, F; Mao, J; Sahasranaman, S; Zhu, R | 1 |
| Brian, W; Giacomini, KM; Giacomini, MM; Horng, H; Humphreys, WG; Kroetz, DL; Lai, Y; Shen, H; Yee, SW | 1 |
2 review(s) available for pravastatin and cyclosporine
| Article | Year |
|---|---|
Membrane transporters in drug development.
Topics: Animals; Computer Simulation; Decision Trees; Drug Approval; Drug Discovery; Drug Evaluation, Preclinical; Drug Interactions; Humans; Membrane Transport Proteins; Mice; Mice, Knockout; Prescription Drugs | 2010 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
17 trial(s) available for pravastatin and cyclosporine
| Article | Year |
|---|---|
Effect of pravastatin in the treatment of hypercholesterolemia after renal transplantation under cyclosporine and prednisone.
Topics: Adult; Apolipoprotein A-I; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cyclosporine; Drug Administration Schedule; Female; Humans; Hypercholesterolemia; Immunosuppression Therapy; Kidney Transplantation; Male; Middle Aged; Muromonab-CD3; Pravastatin; Prednisone | 1995 |
Effect of pravastatin on renal transplant recipients treated with cyclosporine--4-year follow-up.
Topics: Azathioprine; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cyclosporine; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Immunosuppression Therapy; Kidney Transplantation; Male; Pravastatin; Prednisolone; Time Factors; Triglycerides | 1994 |
Clinical efficacy and pharmacokinetics of HMG-CoA reductase inhibitors in heart transplant patients treated with cyclosporin A.
Topics: Alanine Transaminase; Alkaline Phosphatase; Aspartate Aminotransferases; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Creatinine; Cyclosporine; Follow-Up Studies; Heart Transplantation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Pravastatin; Simvastatin; Time Factors; Triglycerides | 1994 |
The effect of pravastatin on acute rejection after kidney transplantation--a pilot study.
Topics: Adult; Anticholesteremic Agents; Cholesterol; Cyclosporine; Cytotoxicity, Immunologic; Enzyme Inhibitors; Female; Graft Rejection; Humans; Immunity, Cellular; Immunosuppressive Agents; Kidney Transplantation; Killer Cells, Natural; Male; Middle Aged; Pilot Projects; Pravastatin; Prednisone | 1996 |
Comparison of pravastatin and lovastatin in renal transplant patients receiving cyclosporine.
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Cyclosporine; Double-Blind Method; Female; Humans; Immunosuppressive Agents; Kidney Transplantation; Lovastatin; Male; Metabolic Clearance Rate; Middle Aged; Pravastatin; Triglycerides | 1996 |
Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses.
Topics: Adult; Analysis of Variance; Anticholesteremic Agents; Area Under Curve; Cyclosporine; Double-Blind Method; Drug Interactions; Drug Therapy, Combination; Graft Rejection; Humans; Immunosuppressive Agents; Kidney Transplantation; Lovastatin; Middle Aged; Pravastatin | 1997 |
The inhibitory effects of pravastatin on natural killer cell activity in vivo and on cytotoxic T lymphocyte activity in vitro.
Topics: Adjuvants, Immunologic; Anticholesteremic Agents; Cells, Cultured; Cholesterol; Cholesterol, LDL; Coronary Disease; Cyclosporine; Disease Progression; Drug Synergism; Female; Graft Rejection; Graft Survival; Heart Transplantation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Incidence; Killer Cells, Natural; Male; Middle Aged; Pravastatin; T-Lymphocytes, Cytotoxic; Transplantation, Homologous | 1998 |
Conversion to tacrolimus to ameliorate cyclosporine toxicity in kidney recipients.
Topics: Adult; Aged; Anticholesteremic Agents; Cyclosporine; Fatty Acids, Monounsaturated; Female; Fluvastatin; Gingival Hyperplasia; Hirsutism; Humans; Hyperlipidemias; Immunosuppressive Agents; Indoles; Kidney Transplantation; Lovastatin; Male; Middle Aged; Pravastatin; Tacrolimus | 1998 |
Effects of simvastatin and pravastatin on hyperlipidemia and cyclosporin blood levels in renal transplant recipients.
Topics: Adult; Cyclosporine; Drug Interactions; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Immunosuppressive Agents; Kidney Transplantation; Male; Pravastatin; Simvastatin | 1999 |
Short-term effects of statin therapy in patients with hyperlipoproteinemia after liver transplantation: results of a randomized cross-over trial.
Topics: Aged; Cholesterol; Cholesterol, LDL; Cross-Over Studies; Cyclosporine; Dose-Response Relationship, Drug; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemias; Immunosuppressive Agents; Liver Transplantation; Male; Middle Aged; Pravastatin; Prospective Studies; Pyridines; Time Factors | 2001 |
Pharmacokinetics of pravastatin in heart-transplant patients taking cyclosporin A.
Topics: Anticholesteremic Agents; Cholesterol; Creatinine; Cyclosporine; Drug Interactions; Drug Monitoring; Female; Heart Transplantation; Humans; Hypercholesterolemia; Immunosuppressive Agents; L-Lactate Dehydrogenase; Male; Middle Aged; Pravastatin; Time Factors; Transferases; Triglycerides | 2002 |
Combined therapy with atorvastatin and calcineurin inhibitors: no interactions with tacrolimus.
Topics: Area Under Curve; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B, Member 1; Calcineurin Inhibitors; Cyclosporine; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Drug Synergism; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Indoles; Lactones; Liver; Liver-Specific Organic Anion Transporter 1; Male; Organic Anion Transporters; Pravastatin; Pyrroles; Simvastatin; Tacrolimus; Time Factors | 2005 |
Ezetimibe for the treatment of uncontrolled hypercholesterolemia in patients with high-dose statin therapy after renal transplantation.
Topics: Adult; Aged; Anticholesteremic Agents; Azetidines; Cholesterol; Cyclosporine; Drug Therapy, Combination; Ezetimibe; Fatty Acids, Monounsaturated; Female; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Kidney Transplantation; Liver; Male; Middle Aged; Muscle, Skeletal; Pravastatin; Simvastatin; Tacrolimus | 2006 |
Effects of pravastatin treatment on blood pressure regulation after renal transplantation.
Topics: Blood Pressure; Cholesterol, HDL; Cholesterol, LDL; Cyclosporine; Death, Sudden, Cardiac; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension, Renal; Immunosuppressive Agents; Kidney; Kidney Transplantation; Male; Middle Aged; Postoperative Complications; Pravastatin; Treatment Failure | 2006 |
Cyclosporine modulation of multidrug resistance in combination with pravastatin, mitoxantrone and etoposide for adult patients with relapsed/refractory acute myeloid leukemia: a phase 1/2 study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclosporine; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Humans; Leukemia, Myeloid, Acute; Mitoxantrone; Pravastatin; Treatment Outcome | 2013 |
Metabolomic and Genome-wide Association Studies Reveal Potential Endogenous Biomarkers for OATP1B1.
Topics: Bile Acids and Salts; Biomarkers; Cyclosporine; Dicarboxylic Acids; Drug Interactions; Fatty Acids; Genome-Wide Association Study; HEK293 Cells; Humans; Liver-Specific Organic Anion Transporter 1; Metabolomics; Myristates; Organic Anion Transport Protein 1; Organic Anion Transporters, Sodium-Independent; Palmitic Acids; Pravastatin | 2016 |
Organic Anion Transporter Polypeptide 1B1 Polymorphism Modulates the Extent of Drug-Drug Interaction and Associated Biomarker Levels in Healthy Volunteers.
Topics: Alleles; Area Under Curve; Biomarkers; Coproporphyrins; Cyclosporine; Drug Interactions; Female; Healthy Volunteers; Heterozygote; Humans; Liver-Specific Organic Anion Transporter 1; Male; Polymorphism, Single Nucleotide; Pravastatin | 2019 |
49 other study(ies) available for pravastatin and cyclosporine
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Carbon metabolism-mediated myogenic differentiation.
Topics: | 2010 |
QSAR-based permeability model for drug-like compounds.
Topics: Caco-2 Cells; Cell Membrane Permeability; Drug Discovery; Humans; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2011 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Molecular characterization of zebrafish Oatp1d1 (Slco1d1), a novel organic anion-transporting polypeptide.
Topics: Animals; Evolution, Molecular; Glycosylation; Gonadal Steroid Hormones; HEK293 Cells; Humans; Ion Transport; Organic Anion Transporters; Protein Multimerization; Zebrafish; Zebrafish Proteins | 2013 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
Myopathy associated with HMG-CoA reductase inhibitors (HMGRIs) and cyclosporin A: evaluation in a rat model.
Topics: Animals; Anticholesteremic Agents; Cyclosporine; Drug Synergism; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Muscles; Muscular Diseases; Necrosis; Pravastatin; Rats; Rats, Inbred Strains; Simvastatin; Structure-Activity Relationship | 1992 |
The effects of pravastatin on hyperlipidemia in renal transplant recipients.
Topics: Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cyclosporine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Kidney Transplantation; Postoperative Complications; Pravastatin; Triglycerides | 1992 |
Altered disposition of pravastatin following concomitant drug therapy with cyclosporin A in transplant recipients.
Topics: Adult; Antibodies; Azathioprine; Cyclosporine; Drug Therapy, Combination; Female; Heart Transplantation; Humans; Immunosuppression Therapy; Male; Middle Aged; Pravastatin; Prednisone | 1993 |
Drugs in cardiac transplantation.
Topics: Anticholesteremic Agents; Antifungal Agents; Cholesterol; Cyclosporine; Drug Interactions; Graft Rejection; Heart Transplantation; Humans; Immunosuppressive Agents; Ketoconazole; Pravastatin | 1996 |
Effects of different inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, pravastatin sodium and simvastatin, on sterol synthesis and immunological functions in human lymphocytes in vitro.
Topics: Cyclosporine; Enzyme Inhibitors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Interleukin-2; Killer Cells, Natural; Lovastatin; Lymphocyte Activation; Lymphocyte Culture Test, Mixed; Lymphocytes; Mevalonic Acid; Phytohemagglutinins; Pravastatin; Simvastatin; Sterols | 1996 |
Combination of pravastatin and cyclosporin in transplant patients.
Topics: Anticholesteremic Agents; Cyclosporine; Drug Interactions; Drug Therapy, Combination; Heart Transplantation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Kidney Transplantation; Pravastatin | 1997 |
Pravastatin increases survival and inhibits natural killer cell enhancement factor in liver transplanted rats.
Topics: Animals; Blood Proteins; Cell Survival; Cyclosporine; Enzyme Inhibitors; Graft Rejection; Heat-Shock Proteins; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Killer Cells, Natural; Liver; Liver Transplantation; Peroxidases; Peroxiredoxins; Pravastatin; Rats; Rats, Inbred Strains; Survival Analysis | 1997 |
Pravastatin and low-dose cyclosporine treatment prevent islet allograft rejection in mice.
Topics: Animals; Cyclosporine; Diabetes Mellitus, Experimental; Graft Rejection; Graft Survival; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Islets of Langerhans Transplantation; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Pravastatin; Transplantation, Homologous | 1998 |
Pravastatin and cyclosporine inhibit platelet-derived growth factor-stimulated vascular smooth muscle cell mitogenesis: an investigation of mechanisms.
Topics: Animals; Aorta; Cell Division; Cells, Cultured; Cyclosporine; DNA; Muscle, Smooth, Vascular; Platelet-Derived Growth Factor; Pravastatin; Rats; Thymidine | 1998 |
Small intestinal metabolism of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor lovastatin and comparison with pravastatin.
Topics: Animals; Aryl Hydrocarbon Hydroxylases; Cyclosporine; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Inhibitors; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Intestine, Small; Ketoconazole; Lovastatin; Male; Microsomes, Liver; Oxidoreductases, N-Demethylating; Pravastatin; Swine; Troleandomycin | 1999 |
Safety of statins (hydroxymethyl glutaryl coenzyme a reductase inhibitors): different mechanisms of metabolism and drug transport may have clinical relevance.
Topics: Aryl Hydrocarbon Hydroxylases; Biological Availability; Cyclosporine; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mixed Function Oxygenases; Practice Guidelines as Topic; Pravastatin; Pyridines; Safety; Steroid 16-alpha-Hydroxylase; Steroid Hydroxylases | 2001 |
Reassuring effect of pravastatin on natural killer cell activity in stable renal transplant patients.
Topics: Anticholesteremic Agents; Azathioprine; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cyclosporine; Cytotoxicity, Immunologic; Humans; Hypercholesterolemia; Immunosuppressive Agents; K562 Cells; Kidney Function Tests; Kidney Transplantation; Killer Cells, Natural; Leukocyte Count; Liver Function Tests; Lymphocyte Count; Postoperative Complications; Pravastatin; Triglycerides | 2001 |
Safety and efficacy of pravastatin therapy for the prevention of hyperlipidemia in pediatric and adolescent cardiac transplant recipients.
Topics: Adolescent; Adult; Child; Cyclosporine; Drug Therapy, Combination; Female; Graft Rejection; Heart Transplantation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Immunosuppression Therapy; Immunosuppressive Agents; Lipids; Male; Pravastatin; Retrospective Studies; Tacrolimus; Transaminases | 2001 |
Transplanted livers and kidneys for HIV+ people.
Topics: Antiretroviral Therapy, Highly Active; Cyclosporine; Hepatitis B; Hepatitis C; HIV Infections; Humans; Hypolipidemic Agents; Kidney Transplantation; Liver Failure; Liver Transplantation; Lovastatin; Pravastatin; Renal Insufficiency; San Francisco | 2001 |
Prolongation of islet allograft survival in mice by combined treatment with pravastatin and low-dose cyclosporine.
Topics: Animals; Blood Glucose; Body Weight; Cyclosporine; Drug Synergism; Graft Survival; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperglycemia; Immunosuppressive Agents; Islets of Langerhans Transplantation; Kidney; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Pravastatin; Transplantation, Homologous | 2001 |
[Utility of pravastin in cardiac transplant dyslipidemia].
Topics: Adult; Aged; Anticholesteremic Agents; Cyclosporine; Heart Transplantation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Immunosuppressive Agents; Male; Middle Aged; Pravastatin; Prospective Studies; Treatment Outcome | 2002 |
Pravastatin treatment attenuates interstitial inflammation and fibrosis in a rat model of chronic cyclosporine-induced nephropathy.
Topics: Animals; Anticholesteremic Agents; C-Reactive Protein; Cyclosporine; Fibrosis; Immunosuppressive Agents; Inflammation Mediators; Kidney; Macrophages; Male; Nephritis; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Osteopontin; Pravastatin; Rats; Rats, Sprague-Dawley; Renin; RNA, Messenger; Sialoglycoproteins; Transforming Growth Factor beta; Transforming Growth Factor beta1 | 2004 |
Pharmacokinetics and pharmacodynamics of pravastatin in pediatric and adolescent cardiac transplant recipients on a regimen of triple immunosuppression.
Topics: Administration, Oral; Adolescent; Anticholesteremic Agents; Area Under Curve; Azathioprine; Calcineurin Inhibitors; Child; Child, Preschool; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cyclosporine; Drug Interactions; Female; Heart Transplantation; Humans; Immunosuppressive Agents; Male; Methylprednisolone; Mycophenolic Acid; Pravastatin; Tacrolimus; Triglycerides | 2004 |
Prevalence of potentially severe drug-drug interactions in ambulatory patients with dyslipidaemia receiving HMG-CoA reductase inhibitor therapy.
Topics: Aged; Ambulatory Care; Aryl Hydrocarbon Hydroxylases; Atorvastatin; Comorbidity; Cross-Sectional Studies; Cyclosporine; Cytochrome P-450 CYP3A; Digoxin; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Male; Niacin; Oxidoreductases, N-Demethylating; Physicians; Pravastatin; Prevalence; Product Surveillance, Postmarketing; Pyrroles; Simvastatin; Time Factors | 2005 |
Combined effects of losartan and pravastatin on interstitial inflammation and fibrosis in chronic cyclosporine-induced nephropathy.
Topics: Animals; C-Reactive Protein; Cyclosporine; Disease Models, Animal; Fibrosis; Inflammation; Kidney; Kidney Diseases; Losartan; Male; Pravastatin; Rats; Rats, Sprague-Dawley | 2005 |
[Hypolipidemic treatment under special conditions: posttransplant and/or immunosuppressive therapy].
Topics: Cyclosporine; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Kidney Transplantation; Lovastatin; Pravastatin; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2005 |
Management of cardiovascular risk in patients receiving calcineurin inhibitors--a case report.
Topics: Acenocoumarol; Amiodarone; Angioplasty; Calcineurin Inhibitors; Carbazoles; Carvedilol; Cyclosporine; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Immunosuppressive Agents; Indoles; Kidney Transplantation; Male; Middle Aged; Myocardial Infarction; Nitroglycerin; Postoperative Complications; Pravastatin; Prednisone; Propanolamines; Risk Factors; Tacrolimus; Treatment Outcome | 2006 |
Amelioration of steroids and cyclosporine-resistant nephrotic syndrome by pravastatin.
Topics: Adolescent; Cyclosporine; Drug Resistance; Female; Humans; Immunosuppressive Agents; Nephrotic Syndrome; Pravastatin; Remission Induction; Steroids | 2007 |
Action profiles of statins and calcineurin inhibitors during human mixed lymphocyte reaction.
Topics: Calcineurin Inhibitors; CD40 Antigens; Cell Proliferation; Cyclosporine; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Indoles; Intercellular Adhesion Molecule-1; Interferon-gamma; Interleukin-12; Interleukin-18; Leukocytes, Mononuclear; Lymphocyte Activation; Lymphocyte Culture Test, Mixed; Mevalonic Acid; Monocytes; Naphthalenes; Oxazines; Pravastatin; T-Lymphocytes; Tacrolimus | 2007 |
The new acyl-CoA cholesterol acyltransferase inhibitor SMP-797 does not interact with statins via OATP1B1 in human cryopreserved hepatocytes and oocytes expressing systems.
Topics: Binding, Competitive; Biological Transport, Active; Cryopreservation; Cyclosporine; Dose-Response Relationship, Drug; Drug Interactions; Estrone; Fluorobenzenes; Hepatocytes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Liver-Specific Organic Anion Transporter 1; Naphthyridines; Oocytes; Organic Anion Transporters; Pravastatin; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2007 |
Safety and efficacy of statin therapy in patients switched from cyclosporine a to sirolimus after cardiac transplantation.
Topics: Adrenal Cortex Hormones; Aged; Atorvastatin; Cholesterol; Cyclosporine; Dyslipidemias; Female; Heart Transplantation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Male; Middle Aged; Postoperative Complications; Pravastatin; Pyrroles; Safety; Sirolimus; Treatment Outcome; Triglycerides | 2008 |
Is cyclosporine A transport inhibited by pravastatin via multidrug resistant protein 2?
Topics: Biological Transport; Caco-2 Cells; Cell Survival; Cyclosporine; Drug Interactions; Female; Fluoresceins; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Immunosuppressive Agents; Middle Aged; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Polymyositis; Pravastatin | 2010 |
Colchicine-induced rhabdomyolysis in a heart/lung transplant patient with concurrent use of cyclosporin, pravastatin, and azithromycin.
Topics: Adult; Anti-Bacterial Agents; Anticholesteremic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Azithromycin; Colchicine; Cyclosporine; Cystic Fibrosis; Drug Interactions; Gout; Gout Suppressants; Heart-Lung Transplantation; Humans; Immunosuppressive Agents; Kidney Failure, Chronic; Male; Multiple Organ Failure; Pravastatin; Rhabdomyolysis | 2011 |
[Prediction of the pharmacokinetic drug-drug interaction of pravastatin and pitavastatin with cyclosporine by a digital liver model based on metabolism and transporter].
Topics: Animals; Area Under Curve; Biological Transport; Computer Simulation; Cyclosporine; Drug Interactions; Humans; Liver; Metabolic Clearance Rate; Models, Biological; Pravastatin; Quinolines | 2011 |
Physiologically based modeling of pravastatin transporter-mediated hepatobiliary disposition and drug-drug interactions.
Topics: Adolescent; Adult; Aged; Area Under Curve; Biological Transport; Cells, Cultured; Computer Simulation; Cyclosporine; Drug Interactions; Enzyme Inhibitors; Female; Gemfibrozil; Hepatocytes; Humans; Liver; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Organic Anion Transporters; Pravastatin; Rifampin; Young Adult | 2012 |
Chronic cyclosporine nephropathy is characterized by excessive autophagosome formation and decreased autophagic clearance.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Acetylcysteine; Animals; Antioxidants; Apoptosis; Autophagy; Caspase 3; Cyclosporine; Deoxyguanosine; Dose-Response Relationship, Drug; Ether-A-Go-Go Potassium Channels; Kidney Diseases; Male; Mice; Microscopy, Electron; Microtubule-Associated Proteins; Oxidative Stress; Phagosomes; Pravastatin; Time Factors | 2012 |
Statin upregulates the expression of klotho, an anti-aging gene, in experimental cyclosporine nephropathy.
Topics: Aging; Animals; Cyclosporine; Glucuronidase; Immunosuppressive Agents; Kidney; Kidney Diseases; Klotho Proteins; Male; Mice; Pravastatin; Up-Regulation | 2012 |
Effect of quercetin on the uptake and efflux of aristolochic acid I from Caco-2 cell monolayers.
Topics: Acetic Acid; Aristolochic Acids; ATP-Binding Cassette Transporters; Benzoic Acid; Biological Transport; Caco-2 Cells; Cells, Cultured; Cyclosporine; Diketopiperazines; Heterocyclic Compounds, 4 or More Rings; Humans; Hydrogen-Ion Concentration; Indomethacin; Intestinal Absorption; Mitoxantrone; Pravastatin; Propionates; Quercetin; Quinidine; Quinolines | 2016 |
Quantitative Analyses of Hepatic OATP-Mediated Interactions Between Statins and Inhibitors Using PBPK Modeling With a Parameter Optimization Method.
Topics: Antibiotics, Antitubercular; Computer Simulation; Cyclosporine; Drug Interactions; Enzyme Inhibitors; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Liver; Models, Biological; Organic Anion Transporters; Pravastatin; Quinolines; Rifampin | 2016 |
Characterization of Long-Lasting Oatp Inhibition by Typical Inhibitor Cyclosporine A and In Vitro-In Vivo Discrepancy in Its Drug Interaction Potential in Rats.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; Cyclosporine; Drug Interactions; Hepatocytes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Midazolam; Organic Anion Transporters; Pravastatin; Protein Binding; Rats; Rats, Sprague-Dawley | 2016 |
Assessment of OATP transporter-mediated drug-drug interaction using physiologically-based pharmacokinetic (PBPK) modeling - a case example.
Topics: Area Under Curve; Cinnamates; Cyclosporine; Drug Interactions; Gemfibrozil; Humans; Indazoles; Liver-Specific Organic Anion Transporter 1; Models, Biological; Pravastatin; Rifampin; Solute Carrier Organic Anion Transporter Family Member 1B3 | 2018 |